DPP4 and plasma cell myeloma: We observed a further increase in CD26 expression on myeloma cells following treatment with panobinostat at 5.0 to 50 nmol/L dose, correlated with dose-dependent enhanced anti-myeloma cytotoxic effect (Fig. 1C; Supplementary Fig. S1).